D
Deconvolvr
United Kingdom · Healthtech
Deconvolvr develops bioinformatics software to interpret molecular signals in cancer biopsy samples and support more personalised treatment decisions.
Separating signals in cancer biopsies
Deconvolvr is developing software that distinguishes cancer, stromal and immune-cell signals within biopsy samples. The company aims to extract information that can improve prognostic testing and help clinicians decide how to treat prostate cancer.
Founded by Dr Axel Thomson and Dr Mark Preston, Deconvolvr is based in Edinburgh. Its work focuses on the interpretation of biological data and the development of tests for more personalised care.
Funding history
1 round · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Accelerator investment | Undisclosed | Bethnal Green Ventures — Role not disclosed |